SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years

Abstract The ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishing large-scale newborn screening programs (NSPs) for metabolic and endocrine disorders in Cuba. This article summarizes the main results of the implementation during the 30 years of SUMA technology in NSP for 5 inherited metabolic diseases, using ultramicroassays developed at the Department of Newborn Screening at the Immunoassay Center. Since 1986, SUMA technology has been used in the Cuban NSP for congenital hypothyroidism, initially studying thyroid hormone in cord serum samples. In 2000, a decentralized program for the detection of hyperphenylalaninemias using heel dried blood samples was initiated. These successful experiences permitted including protocols for screening congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency in 2005. A program for the newborn screening of CH using the thyroid-stimulating hormone Neonatal ultramicro-ELISA was fully implemented in 2010. Nowadays, the NSP is supported by a network of 175 SUMA laboratories. After 30 years, more than 3.8 million Cuban newborns have been screened, and 1002 affected children have been detected. Moreover, SUMA technology has been presented in Latin America for over 2 decades and has contributed to screen around 17 million newborns. These results prove that developing countries can develop appropriate diagnostic technologies for making health care accessible to all.

Saved in:
Bibliographic Details
Main Authors: Reyes,Ernesto Carlos González, Castells,Elisa M., Frómeta,Amarilys, Arteaga,Ana Luisa, Río,Lesley Del, Tejeda,Yileidis, Pérez,Pedro L., Segura,Mary Triny, Almenares,Pedro, Perea,Yenitse, Carlos,Niurka M., Robaina,René, Fernández-Yero,José L.
Format: Digital revista
Language:English
Published: Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT) 2016
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100313
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2326-45942016000100313
record_format ojs
spelling oai:scielo:S2326-459420160001003132019-05-28SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 YearsReyes,Ernesto Carlos GonzálezCastells,Elisa M.Frómeta,AmarilysArteaga,Ana LuisaRío,Lesley DelTejeda,YileidisPérez,Pedro L.Segura,Mary TrinyAlmenares,PedroPerea,YenitseCarlos,Niurka M.Robaina,RenéFernández-Yero,José L. SUMA technology newborn screening UMTEST UMELISA Abstract The ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishing large-scale newborn screening programs (NSPs) for metabolic and endocrine disorders in Cuba. This article summarizes the main results of the implementation during the 30 years of SUMA technology in NSP for 5 inherited metabolic diseases, using ultramicroassays developed at the Department of Newborn Screening at the Immunoassay Center. Since 1986, SUMA technology has been used in the Cuban NSP for congenital hypothyroidism, initially studying thyroid hormone in cord serum samples. In 2000, a decentralized program for the detection of hyperphenylalaninemias using heel dried blood samples was initiated. These successful experiences permitted including protocols for screening congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency in 2005. A program for the newborn screening of CH using the thyroid-stimulating hormone Neonatal ultramicro-ELISA was fully implemented in 2010. Nowadays, the NSP is supported by a network of 175 SUMA laboratories. After 30 years, more than 3.8 million Cuban newborns have been screened, and 1002 affected children have been detected. Moreover, SUMA technology has been presented in Latin America for over 2 decades and has contributed to screen around 17 million newborns. These results prove that developing countries can develop appropriate diagnostic technologies for making health care accessible to all.info:eu-repo/semantics/openAccessLatin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)Journal of Inborn Errors of Metabolism and Screening v.4 20162016-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100313en10.1177/2326409816661356
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Reyes,Ernesto Carlos González
Castells,Elisa M.
Frómeta,Amarilys
Arteaga,Ana Luisa
Río,Lesley Del
Tejeda,Yileidis
Pérez,Pedro L.
Segura,Mary Triny
Almenares,Pedro
Perea,Yenitse
Carlos,Niurka M.
Robaina,René
Fernández-Yero,José L.
spellingShingle Reyes,Ernesto Carlos González
Castells,Elisa M.
Frómeta,Amarilys
Arteaga,Ana Luisa
Río,Lesley Del
Tejeda,Yileidis
Pérez,Pedro L.
Segura,Mary Triny
Almenares,Pedro
Perea,Yenitse
Carlos,Niurka M.
Robaina,René
Fernández-Yero,José L.
SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
author_facet Reyes,Ernesto Carlos González
Castells,Elisa M.
Frómeta,Amarilys
Arteaga,Ana Luisa
Río,Lesley Del
Tejeda,Yileidis
Pérez,Pedro L.
Segura,Mary Triny
Almenares,Pedro
Perea,Yenitse
Carlos,Niurka M.
Robaina,René
Fernández-Yero,José L.
author_sort Reyes,Ernesto Carlos González
title SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
title_short SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
title_full SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
title_fullStr SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
title_full_unstemmed SUMA Technology and Newborn Screening Tests for Inherited Metabolic Diseases in Cuba: An Overview of the First 30 Years
title_sort suma technology and newborn screening tests for inherited metabolic diseases in cuba: an overview of the first 30 years
description Abstract The ultramicroanalytic system (SUMA), created in the 1980s, is a complete system of reagents and instrumentation to perform ultramicroassays combining the sensitivity of the micro-enzyme-linked immunosorbent assay (ELISA) tests with the use of ultramicrovolumes. This technology permitted establishing large-scale newborn screening programs (NSPs) for metabolic and endocrine disorders in Cuba. This article summarizes the main results of the implementation during the 30 years of SUMA technology in NSP for 5 inherited metabolic diseases, using ultramicroassays developed at the Department of Newborn Screening at the Immunoassay Center. Since 1986, SUMA technology has been used in the Cuban NSP for congenital hypothyroidism, initially studying thyroid hormone in cord serum samples. In 2000, a decentralized program for the detection of hyperphenylalaninemias using heel dried blood samples was initiated. These successful experiences permitted including protocols for screening congenital adrenal hyperplasia, galactosemia, and biotinidase deficiency in 2005. A program for the newborn screening of CH using the thyroid-stimulating hormone Neonatal ultramicro-ELISA was fully implemented in 2010. Nowadays, the NSP is supported by a network of 175 SUMA laboratories. After 30 years, more than 3.8 million Cuban newborns have been screened, and 1002 affected children have been detected. Moreover, SUMA technology has been presented in Latin America for over 2 decades and has contributed to screen around 17 million newborns. These results prove that developing countries can develop appropriate diagnostic technologies for making health care accessible to all.
publisher Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100313
work_keys_str_mv AT reyesernestocarlosgonzalez sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT castellselisam sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT frometaamarilys sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT arteagaanaluisa sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT riolesleydel sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT tejedayileidis sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT perezpedrol sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT seguramarytriny sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT almenarespedro sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT pereayenitse sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT carlosniurkam sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT robainarene sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
AT fernandezyerojosel sumatechnologyandnewbornscreeningtestsforinheritedmetabolicdiseasesincubaanoverviewofthefirst30years
_version_ 1756441176926322688